A Multiple Center Randomized, Double-Blind, Single-Ascending-Dose, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics Following Oral Administration of RO5024048 in Healthy Japanese and Caucasian Subjects
Phase of Trial: Phase I
Latest Information Update: 10 Jun 2016
At a glance
- Drugs Mericitabine (Primary)
- Indications Hepatitis C
- Focus Pharmacokinetics
- Sponsors Roche
- 24 Mar 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 24 Mar 2011 Actual end date (Feb 2011) added as reported by ClinicalTrials.gov.
- 17 Jul 2010 Last checked against Roche record.